Chronic Sinusitis
Chronic Rhinosinusitis (CRS) is one of the most common long-term illnesses in the U.S. and affects nearly 30 million Americans annually. Symptoms include inflammation, nasal congestion, reduced sense of smell and facial pain and often results in decreased productivity and sleep, missed work days and diminished quality of life.
Unfortunately, 52% of patients fail to respond to standard treatments of antibiotics, steroids and nasal sprays, and many are reluctant to undergo invasive surgery with significant failure rates.
A New Pathway:
The SinusLogic™ Stent
Sinopsys has submitted a US clinical trial design to evaluate the safety and efficacy of saline delivery through the SinusLogic™ Stent, for the treatment of Chronic Sinusitis patients.
The SinusLogic™ Stent is a small, flexible silicone tube placed in the soft tissue adjacent to the tear duct in a 20-minute in-office procedure. The stent provides direct access to the Ethmoid Sinus – a common (often inaccessible) site of inflammation in CRS patients. By utilizing daily saline eye drops, this targeted means of irrigation may offer an effective treatment option, potentially reducing the frequent use of antibiotics and need for invasive surgery.
Caution – Investigational Device, Limited by Federal (or United States) Law to Investigational Use.
Dedicated to finding new solutions for chronic sinusitis
Founded by physicians and advised by a highly skilled, experienced team of ENTs and healthcare executives, we are committed to developing novel therapies for our patients.
Our mission is to pioneer innovative treatments that provide lasting relief and improve the quality of life for those affected by sinusitis.
Dedicated to finding new solutions for chronic sinusitis
Founded by physicians and advised by a highly skilled, experienced team of ENTs and healthcare executives to create novel therapies for sinusitis patients.
